Water Vapor Ablation for Grade Group 3 Prostate Cancer

Vanquish® Water Vapor Ablation for Grade Group 3 PrOstate CanceR: A Multicenter Single Arm Study

The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.

Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.

Inclusion Criteria:

• Participant has been diagnosed with Grade Group 3 (GG3) intermediate-risk prostate cancer.

• ≤20 ng/ml prostate specific antigen (PSA).

• Prostate volume of 20-80cc per Central Imaging read.

• ≥50 years of age; with life expectancy of ≥10 years.

• Clinical cancer stage less than or equal to T2c (tumor may involve both sides of the prostate but without evidence that tumor extends outside of the prostate and with no cancer cells found in nearby lymph nodes) evaluated by prostate specific membrane antigen positron emission tomography (PSMA PET) scan.

• Within 6 months prior to signing consent have had a multiparametric MRI (mpMRI).

  a.) mpMRI results must show localized disease meaning a single MRI region of suspicion (PI-RADS lesion volume ≤2.25cc with a maximum lesion diameter <17mm as measured by diffusion weighted imaging (DWI) determined by Central Imaging).

• Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal).

  1. Minimum of 2 targeted cores from a single ROI identified by Central Imaging review, and at least one core confirming GG3 disease on biopsy (lesion may cross the midline); Gleason Grade Group determined by highest Gleason score of the targeted core.
  2. GG1 cores from anywhere in the prostate are acceptable.
  3. Less than 50% of systematic biopsy cores are positive for GG1 disease. For the <50% calculation, all positive cores located in the target, are counted as "one core."
  4. All positive GG2 or GG3 cores must be located in the lesion, or immediately adjacent to the lesion, as determined by the fusion system's tracking, mapping and imaging documentation features.
  5. Additional MRI regions of suspicion that are Central Imaging confirmed PI-RADS ≤3 that are negative on biopsy or GG1 are acceptable.

• Within 6 months prior to signing consent have had a PSMA-PET scan.

  1. PSMA-PET scan results show no suspicion of metastasis as determined by site read.
  2. Per Central Imaging, PSMA-PET scan prostate results are concordant with mpMRI results
  3. If PSMA-PET scan indicates an additional area of suspicion from the planned treatment area, a targeted repeat biopsy is required to rule out ≥ GG2.

• Participant is willing and able to adhere to specific protocol visits and required testing, including completion of all questionnaires, throughout study.

• Participant is geographically stable and near the site or able and willing to travel back to site for follow-up visits.

• Participant is able and willing to provide written consent to participate in the study.

Exclusion Criteria:

• MRI evidence of extracapsular extension of cancer (MRI read as capsular invasion, bulge, or frank ECE) as determined by Central Imaging.

• Any additional Central Imaging confirmed PI-RADS 4 or 5 suspicious lesions.

• Participants with ≥GG4 cores anywhere in the prostate.

• Participants with GG2 or GG3 cores outside the region of interest.

• Contraindications per the Vanquish Instructions for Use.

• Any previous treatment for prostate cancer or any prior surgery, intervention, or minimally invasive therapy (MIST) for the prostate or bladder neck, including but not limited to Vanquish therapy, TUIP, TURP, Aquablation, Green Light, Rezūm, Prostatic Urethral Lift, iTind, Prostatic Arterial Embolization, or microwave therapy.

• Currently taking medications that have hormonal effects on the prostate or PSA, such as:

  1. 5 alpha reductase inhibitors, if on for < 6 months (6-month washout required if participant is able and willing to stop medication),
  2. Androgen blockers,
  3. Luteinizing hormone-releasing hormone agonists or antagonists within the past 12 months,
  4. or Testosterone supplementation, if on for < 3 months (3-month washout required if participant is able and willing to stop medication)
  5. A participant on benign prostatic hyperplasia medication which does not affect the PSA can be included.

• Treated within the past 5 years for a lower and/or upper urinary tract malignancy.

• Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life (QOL) questionnaires.

• Participant currently participating in other prostate tissue and/or cancer study unless approved by Sponsor in writing.

• Participant is considered vulnerable, such as incarcerated or cognitively impaired.